About ASTEPRO

Approved by the FDA in October 2008, ASTEPRO is a nasal antihistamine spray created to meet the needs of patients 12 years of age and older with seasonal allergic rhinitis. Its active ingredient is azelastine hydrochloride, a medicine with an established safety and efficacy profile.

ASTEPRO is azelastine in a unique vehicle formulated for improved tolerability:

  • Powerful efficacy. In a pivotal clinical study comparing ASTEPRO with placebo, patients treated with ASTEPRO two sprays per nostril BID, experienced a significantly greater improvement in symptoms than patients treated with placebo.1,2
  • Rapid relief. In a pivotal clinical study, patients experienced relief in as early as 30 minutes.2,3
  • Improved tolerability. In pivotal clinical study 7% of patients using ASTEPRO two sprays per nostril BID, reported a bitter taste after use and 2% reported feeling drowsy. Fewer than 1% of people stopped using ASTEPRO due to side effects. 1

Find out more about ASTEPRO:

  • Prescribing & Dosing – Starting dose, how it is supplied, and how to use the spray bottle
  • Efficacy – Assessment of the efficacy of ASTEPRO based on the 12-hour reflective Total Nasal Symptom Score
  • Tolerability – In a pivotal clinical study , fewer than 1% of patients discontinued due to adverse reactions
  • Clinical Pharmacology – Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H1-receptor antagonist activity

1 ASTEPRO package insert. Somerset, NJ: Meda Pharmaceuticals Inc; 2008.